10-Q: TG Therapeutics Posts Strong Q2, Shifts to Profit

TG Therapeutics reported significant revenue growth and a return to profitability in Q2 2025, driven by strong BRIUMVI sales and pipeline advancements.

Summary

• Total revenue for the six months ended June 30, 2025, increased by 91.4% to $262.0 million, up from $136.9 million in the same period of 2024.
• Product revenue, net, primarily from U.S. sales of BRIUMVI, grew by 110% to $258.5 million for the six months ended June 30, 2025, compared to $123.1 million in 2024.
• The company achieved a net income of $33.2 million for the six months ended June 30, 2025, a significant improvement from a net loss of $3.8 million in the prior year period.
• Operating income for the six months ended June 30, 2025, was $43.5 million, compared to an operating loss of $0.454 million in the same period of 2024.
• Research and development expenses increased by 55.3% to $78.1 million for the six months ended June 30, 2025, driven by ublituximab subcutaneous development and increased clinical trial expenses.
• Selling, general and administrative expenses rose by 44.3% to $105.9 million for the six months ended June 30, 2025, due to increased commercialization costs for BRIUMVI.
• Cash and cash equivalents, along with investment securities, totaled $278.9 million as of June 30, 2025.
• The company repurchased 193,500 shares of common stock for $6.9 million during the three months ended June 30, 2025, as part of its $100 million share repurchase program, with $78.2 million remaining.
• The 2022 Incentive Plan was amended to increase authorized shares for issuance from 17,000,000 to 22,000,000, pending shareholder approval at the 2025 annual meeting.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with a significant increase in product revenue and a shift to net profitability. Pipeline advancements are promising, and the share repurchase program indicates management confidence. However, increased cash burn from operations and reliance on third parties present some challenges.

Positives

• Strong product revenue growth for BRIUMVI, increasing 110% year-over-year to $258.5 million for the six months ended June 30, 2025, indicating successful market penetration.
• Achieved net income of $33.2 million for the six months ended June 30, 2025, a significant turnaround from a net loss of $3.8 million in the prior year, demonstrating improved financial health.
• Positive operating income of $43.5 million for the six months ended June 30, 2025, compared to a loss in the prior period, reflecting operational efficiency gains.
• Advancements in pipeline with the initiation of a Phase 3 pivotal program for subcutaneous BRIUMVI and the dosing of the first patient in a Phase 1 trial for azer-cel in progressive multiple sclerosis.
• Expansion of BRIUMVI's global reach with commercial launch in the EU by Neuraxpharm and approvals in Switzerland and Australia.
• Issuance of three additional patents for BRIUMVI by the USPTO, extending patent protection through 2042, enhancing intellectual property strength.
• Active share repurchase program, with $6.9 million in repurchases during Q2 2025 and $78.2 million remaining, signaling confidence in valuation and commitment to shareholder returns.

Negatives

• License, milestone, royalty, and other revenue decreased significantly by 75% to $3.5 million for the six months ended June 30, 2025, primarily due to a large milestone payment in the prior year not recurring.
• Net cash used in operating activities increased to $21.3 million for the six months ended June 30, 2025, compared to $2.7 million in the prior year, indicating higher cash burn from operations.
• Increased research and development expenses by 55.3% to $78.1 million for the six months ended June 30, 2025, reflecting higher costs for pipeline development.
• Selling, general and administrative expenses increased by 44.3% to $105.9 million for the six months ended June 30, 2025, due to higher commercialization costs.
• Increased interest expense to $13.5 million for the six months ended June 30, 2025, mainly due to the $250 million Initial Term Loan with Blue Owl.

Risks

• Failure to achieve broad market acceptance for BRIUMVI and future product candidates among physicians, patients, and healthcare payors could limit revenues.
• Regulatory approvals for products may be subject to limitations on indicated uses or require costly post-marketing studies, potentially impacting commercial potential.
• Approved products, including BRIUMVI, may cause undesirable side effects after commercialization, leading to significant negative consequences like regulatory withdrawal or product liability lawsuits.
• Market opportunities for BRIUMVI and product candidates like azer-cel may be smaller than estimated, adversely affecting revenue and profitability.
• Substantial competition from other pharmaceutical and biotechnology companies, potentially leading to others commercializing drugs more successfully.
• Products may become subject to unfavorable pricing regulations or third-party payor coverage and reimbursement policies, harming the business.
• Incurrence of significant operating losses since inception, with potential for future losses, requiring substantial revenue generation to maintain profitability.
• Potential need for additional capital, which if unavailable, could delay, limit, reduce, or eliminate drug development programs or commercialization efforts, and may cause dilution to stockholders.
• High level of indebtedness and debt service obligations could adversely affect financial condition and make funding operations more difficult.
• Reliance on third parties for clinical, preclinical data generation, clinical trial conduct, and manufacturing, increasing risks of insufficient supply, quality issues, or delays.
• Dependence on single-source suppliers for critical materials (starting materials, API/drug substance, drug product), making the company vulnerable to supply disruptions.
• Disputes or non-performance by licensors could adversely affect the ability to develop and commercialize licensed products.
• Challenges in obtaining and protecting intellectual property, including patents, which if not sufficiently broad or are challenged, could impair commercialization.
• Difficulty in attracting and retaining key management, commercial, and clinical development personnel, which could impede business strategy and objectives.
• Challenges in managing business development and expansion, potentially leading to operational disruptions.
• Internal information technology systems or those of third-party contractors may fail or suffer security breaches, disrupting development programs and commercialization.
• Unfavorable global economic conditions, including high inflation, interest rates, and geopolitical conflicts, could adversely affect business and capital raising.
• Risk of employee, investigator, or consultant misconduct, including non-compliance with regulatory standards and insider trading, leading to sanctions or reputational harm.
• Potential adverse legislative or regulatory tax changes, such as the R&D amortization requirement, could negatively impact financial condition.
• Stock price volatility and potential future sales of common stock could cause price declines.
• Risks related to corporate social responsibility and reputational matters, including negative publicity or failure to meet ESG expectations.
• Climate change or related legal/regulatory measures may negatively affect business, supply chain, and financial condition.

Future Outlook

The company anticipates that its current cash, cash equivalents, and investment securities, combined with projected future revenues, will provide sufficient liquidity for more than a twelve-month period from the filing date. It expects to continue incurring significant research and development, commercialization, and outsourced manufacturing expenses for BRIUMVI and other drug candidates. The company may need significant future financing to execute ongoing and future operations, and its ability to maintain profitability depends on generating substantial and sustained revenues from BRIUMVI and future approved products.

Management Comments

• We anticipate that our cash, cash equivalents, and investment securities, combined with projected future revenues will provide sufficient liquidity for more than a twelve-month period from the date of filing this Quarterly Report on Form 10-Q.
• The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, our commercialization efforts for BRIUMVI and the timing, design and conduct of clinical trials for our drug candidates as well as the costs associated with licensing or otherwise acquiring new product candidates.
• We may be dependent upon significant future financing to provide the cash necessary to execute our ongoing and future operations.
• We expect to continue to incur significant research and development expenses, as well as significant commercialization and outsourced manufacturing expenses as we continue to commercialize BRIUMVI.
• We expect that healthcare reform measures that may be adopted in the future, may result in increased manufactured financial liability and additional downward pressure on the price that we may receive for any of our product candidates, if approved.

Industry Context

The biopharmaceutical industry is highly competitive and capital-intensive, with significant focus on B-cell diseases, neurological, and immunological fields. TG Therapeutics' strong revenue growth for BRIUMVI in RMS positions it well against competitors, but the industry faces ongoing pressures from pricing regulations, reimbursement policies, and the need for continuous innovation. The shift towards allogeneic CAR T therapies for autoimmune diseases, as pursued with azer-cel, represents a cutting-edge area of development with high potential but also significant regulatory and commercial hurdles. The increasing scrutiny on drug pricing and the evolving regulatory landscape, including the impact of acts like the OBBBA, reflect broader industry challenges related to affordability and access to prescription drugs.

Comparison to Industry Standards

• TG Therapeutics' 110% year-over-year product revenue growth for BRIUMVI significantly outperforms many established pharmaceutical companies, indicating strong market penetration for a relatively new commercial product. For instance, while large pharma might see single-digit to low double-digit growth for mature products, this level of growth is more typical for successful new drug launches in specialized markets.
• The transition from a net loss of $3.8 million to a net income of $33.2 million within six months demonstrates a rapid improvement in financial performance, which is a positive indicator compared to many early-to-mid-stage biopharmaceutical companies that often sustain losses for longer periods post-commercialization.
• The increase in R&D expenses by 55.3% to $78.1 million is consistent with a biopharmaceutical company actively advancing its pipeline, particularly with the development of a subcutaneous formulation of an approved drug (BRIUMVI) and a novel CAR T therapy (azer-cel). This level of investment is comparable to peers in the neurology and immunology space, such as Biogen or Novartis, who also invest heavily in new formulations and advanced therapies.
• The company's reliance on single-source third-party manufacturers for BRIUMVI, like Samsung Biologics, is a common industry practice for specialized biologics but also represents a concentration risk that larger, more diversified companies might mitigate through multi-source strategies.
• The share repurchase program of up to $100 million, with $78.2 million remaining, aligns with practices of more mature, profitable companies aiming to return value to shareholders, distinguishing TG Therapeutics from many development-stage biotechs that primarily focus on capital raises.

Corporate Governance

Legal Proceedings

• The company and its subsidiaries are not a party to, and their property is not the subject of, any material pending legal proceedings.

Related Party Transactions

• The company has a Shared Services Agreement with Fortress Biotech, Inc. (FBIO) to share costs for facilities, personnel, and other overhead. Expenses incurred under this agreement were approximately $0.8 million for the six months ended June 30, 2025.
• Mr. Weiss, the company's Chairman and Chief Executive Officer, also serves as a director and Executive Vice Chairman, Strategic Development of FBIO.
• The company has an Office Agreement with FBIO, requiring payment of a share of average annual rent and other costs, approximating $1.8 million annually. A $1.3 million security deposit is pledged for this agreement.

Stakeholder Impact

• **Shareholders**: Positive impact from strong revenue growth, net income, and the share repurchase program, potentially leading to increased share value. However, potential future dilution from capital raises and increased authorized shares for incentive plans could be a concern.
• **Employees**: Increased headcount and stock price at which equity awards were granted suggest positive impact on employee compensation and retention. Continued R&D and commercialization efforts indicate job stability and growth opportunities.
• **Customers (Healthcare Providers/Patients)**: Continued commercialization and global expansion of BRIUMVI provides broader access to treatment for RMS patients. Development of subcutaneous BRIUMVI aims to offer more convenient administration options. Azer-cel development targets unmet needs in progressive MS.
• **Suppliers/Contract Manufacturers**: Increased manufacturing expenses and reliance on single-source suppliers like Samsung Biologics indicate continued business for these partners, but also highlight the company's dependence on their performance and compliance.
• **Creditors**: The $250 million term loan facility with Blue Owl Capital Corporation indicates a significant debt obligation, but the company's improved profitability and liquidity position suggest a stronger ability to meet these obligations.

Next Steps

• Continue commercialization efforts for BRIUMVI in the U.S. and ex-U.S. markets.
• Initiate patient enrollment for the Phase 3 pivotal program evaluating a consolidated Day 1 and Day 15 dosing regimen for IV BRIUMVI in the ENHANCE trial.
• Commence patient enrollment for the Phase 3 pivotal program evaluating subcutaneous BRIUMVI in patients with relapsing forms of MS, assessing every other month and quarterly dosing schedules.
• Continue clinical development of azer-cel for progressive forms of MS, following the dosing of the first patient in a Phase 1 trial.
• Evaluate the impact of the newly enacted One Big Beautiful Bill Act (OBBBA) on the company's forecasted annual effective tax rate in subsequent periods.
• Seek shareholder approval for the amendment to the 2022 Incentive Plan to increase authorized shares at the 2025 annual meeting.

Key Dates

Recommendation

The company has demonstrated exceptional commercial execution with BRIUMVI, evidenced by a 110% increase in product revenue and a significant shift from net loss to net income. This strong financial turnaround, coupled with advancements in its pipeline (SubQ BRIUMVI and azer-cel entering pivotal/early-stage trials), indicates robust growth potential. While expenses have increased and there's reliance on third parties, these are typical for a growing biopharmaceutical company. The ongoing share repurchase program further signals management's confidence in the company's valuation and commitment to shareholder returns. The positive momentum in commercialization and pipeline development outweighs the inherent risks of the industry, making it an attractive investment.

Keywords

Biopharmaceutical, Multiple Sclerosis, RMS, BRIUMVI, Ublituximab, Azer-cel, CAR T therapy, B-cell diseases, Clinical Trials, FDA Approval, Commercialization, Drug Development, Biotech, Pharmaceutical, SEC Filing, 10-Q, Financial Results, Stock Repurchase